Komodo Health and the University of Washington CHOICE Institute partner to progress real-world health economics and outcomes research

CHOICE Institute of the University of Washington School of Pharmacy chooses Komodo Health to be their new real-world data (RWD) and technology partner to advance health economics and outcomes research (HEOR).

Komodo Health has announced they have been selected by the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute of the University of Washington’s School of Pharmacy for a collaboration to drive real-world insights in comparative outcomes and cost-effectiveness research and analytics. The alliance will see Komodo’s comprehensive RWD reservoir and AI-enabled analytics software used in real-world HEOR across a wide range of therapeutic areas in the US.

“After reviewing data and technology platforms across the industry, we felt the quality and depth of Komodo’s data, combined with its flexible technology infrastructure, would uniquely position our team to conduct a wide range of advanced research across health economics, outcomes, and comparative effectiveness,” voiced Anirban Basu, PhD, Stergachis Family Endowed Director and Professor of Health Economics at The CHOICE Institute — a premier hub for generating knowledge to improve individual and population health through transformative learning, research, and dissemination about the effectiveness, safety, and value of medical products, services, and policies.

As new data and technology partner to the CHOICE Institute, Komodo will contribute its renowned Healthcare Map of comprehensive longitudinal patient-level RWD for hundreds of millions of individuals in the US, enhanced with additional data layers including mortality insights, race, ethnicity, and other demographic characteristics. This vast resource will be deployed in powerful combination with the advanced algorithms and machine learning powered solutions of Komodo’s Sentinel software, to connect the dots between individual patient journeys and large-scale health outcomes.

Komodo’s combined data and analytics will enable CHOICE Institute researchers to better model the real-world clinical and financial impacts of new therapies across patient populations. These insights will be generated across a wide range of therapeutic areas, including diabetes, dementia, sickle cell disease, pain management, cystic fibrosis and hepatitis C. Researchers will study the intersection of health policy, chronic disease management, and cognition; the value of care for conditions influencing healthy aging; vaccinations; antibiotic use; care locations; patient reimbursement; health economics and comparative effectiveness; and more. Together these will inform decision-making, close gaps in care, address disease burden, and help the alliance create a more cost-effective, value-driven healthcare system.

“The University of Washington is world-renowned for producing some of the most innovative health economics and outcomes research, so it is an honor to work together to advance critical areas of study,” commented Web Sun, President and Co-Founder of Komodo Health. “With Komodo’s diverse array of data sources, unique level of data context, and highly flexible technology platform, we are helping to build the foundation for how academic institutions and HEOR teams can more quickly produce high-quality research and evidence on disease burden and healthcare outcomes.”